CeriBell (NASDAQ:CBLL) Reaches New 1-Year Low – Here’s What Happened

by · The Markets Daily

CeriBell (NASDAQ:CBLL – Get Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as $22.81 and last traded at $22.91, with a volume of 47261 shares. The stock had previously closed at $24.29.

Analysts Set New Price Targets

CBLL has been the subject of several recent analyst reports. TD Cowen upped their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. started coverage on CeriBell in a research note on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective on the stock. Bank of America began coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price for the company. Canaccord Genuity Group began coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price objective on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $32.60.

Get Our Latest Stock Report on CBLL

CeriBell Trading Down 5.2 %

The firm has a 50 day moving average price of $27.56.

CeriBell (NASDAQ:CBLL – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million. On average, equities research analysts forecast that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

(Get Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Further Reading